Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12304379 | 0.77 | TP53 (0.47) | ALPL | |
| SCHEMBL171413 | 0.76 | MAPK1 (0.67) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL68056 | 0.76 | MAPK1 (1.00) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL285996 | 0.76 | MAPK1 (0.67) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL30614240 | 0.74 | MAPK1 (0.96) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL286531 | 0.74 | MAPK1 (0.65) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL30107039 | 0.74 | MAPK1 (0.70) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL20517628 | 0.74 | MAPK1 (0.65) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL21630583 | 0.74 | MAPK1 (0.65) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL1812854 | 0.73 | MAPK1 (0.79) | MAPK1GAAALPLMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | MAPK1 593/4885GAA 824/4885ALPL 3482/4885 |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MAPK1 593/4885GAA 824/4885ALPL 3482/4885 |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | KIT, FLT3, FER | MAPK1 583/4885GAA 794/4885ALPL 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.